Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916578 · ClinicalTrials.gov registry record · Phase 2
Xeloda (Capecitabine) and External Beam Radiation
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00916578: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00916578 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00916578, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy. The safety of this study treatment will also be studied.
Interventions
- DRUG Capecitabine
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-06-05 |
| Est. Completion | 2017-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916578
The ClinicalTrials.gov registry entry for NCT00916578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00916578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916578 about?
NCT00916578 is a clinical study titled "Xeloda (Capecitabine) and External Beam Radiation". The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy. The safety of this study treatment will also be studied.
What is the current status of trial NCT00916578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-06-05. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT00916578?
The interventions under investigation include: Capecitabine (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00916578?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.